Skip to main content

Aimovig Side Effects

Generic name: erenumab

Medically reviewed by Philip Thornton, DipPharm. Last updated on Feb 29, 2024.

Note: This document contains side effect information about erenumab. Some dosage forms listed on this page may not apply to the brand name Aimovig.

Applies to erenumab: subcutaneous solution.

Serious side effects of Aimovig

Along with its needed effects, erenumab (the active ingredient contained in Aimovig) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking erenumab:

Less common

Incidence not known

Other side effects of Aimovig

Some side effects of erenumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common

For Healthcare Professionals

Applies to erenumab: subcutaneous solution.


The more commonly reported adverse reactions have included injection site reactions and constipation.[Ref]


Postmarketing reports: Hypersensitivity reactions including rash, angioedema, and anaphylaxis


Common (1% to 10%): Constipation

Postmarketing reports: Constipation with serious complications, oral mucosal ulceration

During clinical trials, constipation was reported in 3% of patients receiving 140 mg/month and 1% of patients receiving 70 mg/month. In the postmarketing period, serious complications of constipation have been reported. In most cases of serious constipations, this drug was discontinued.


Postmarketing reports: Hypertension and worsening of preexisting hypertension


Common (1% to 10%): Injection site reactions

Frequency not reported: Injection site erythema, injection site pruritus, injection site pain

Injection site reactions included reports such as injection site pain and injection site erythema. Injection site reactions were reported in 6%, 5%, and 3% of patients receiving 70 mg/month, 140 mg/month, and placebo, respectively.


Common (1% to 10%): Cramps, muscle spasms


Common (1% to 10%): Fatigue


Common (1% to 10%): Pruritus

Postmarketing reports: Alopecia, rash

Frequently asked questions


1. Product Information. Aimovig (erenumab). Amgen USA. 2018.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.